Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Synthetic Blood (SYBD) -- Ignore unavailable to you. Want to Upgrade?

To: Lance who wrote (212)	8/6/1998 5:04:00 PM
From: t.gawarecki	Respond to of 307

Lance, Have any ideas what has been going on the last couple of days. Today was more encouraging to see the buying coming in. I wonder if this is more insider selling or a negative reaction to th e10-K and general market negativity. Tom

To: Lance who wrote (212)	8/6/1998 5:08:00 PM
From: t.gawarecki	Read Replies (2) \| Respond to of 307

NOW I SEE! NEWS!!! Synthetic Blood International Announces Product Development, Marketing Agreement Business Wire - August 06, 1998 14:14 KETTERING, Ohio--(BW HealthWire)--Aug. 6, 1998--Synthetic Blood International Inc. (OTCBB:SYBD) announced today that it will sign a letter of intent to enter into an agreement with Chi Sheng Chemical Corp., a leading pharmaceutical company in Taiwan. The agreement will cover product development and marketing for Oxycyte(TM), the company's perfluorocarbon-based blood substitute. Chi Sheng markets a full range of pharmaceuticals and is the largest manufacturer of large volume parenteral solutions in Taiwan. The company recently opened a manufacturing facility for parenteral nutritional emulsions and, therefore, has the capability to manufacture Oxycyte once the manufacturing process has been adapted to their equipment. "This is an exciting development which represents the first step toward implementing our Far East marketing strategy," said Dr. Robert Tao, SYBD's agent for Far East partner recruitment, who will negotiate the agreement with Chi Sheng. "Because of their experience and capabilities, we believe that Chi Sheng is uniquely qualified and is the right partner for Oxycyte in Taiwan." Tao, a native of Taiwan, is an expert in emulsion formulation and production with more than 25 years experience in pharmaceutical development and manufacturing in the U.S., Switzerland and the Far East. During the last four years with Lipoid Co., Ltd, of Kowloon, Hong Kong, he developed business relations with many pharmaceutical companies in the region. "We believe this development will culminate in an Oxycyte licensing agreement for Taiwan between our Company and Chi Sheng." said Robert Nicora, president. In addition to developing Oxycyte, the company is developing Fluorovent(TM), a perfluorocarbon liquid ventilation product; and an implanted biosensor for continuously monitoring blood glucose levels in diabetics. SYBD is located in Kettering, Ohio and has a West Coast office in Irvine, Calif. The company's stock is traded on the OTC Electronic Bulletin Board, symbol SYBD. CONTACT: Synthetic Blood International, Inc. Joan Mahan, 800/809-6054